SG11201804020YA - Assays and methods for selecting a treatment regimen for a subject with leukemia - Google Patents

Assays and methods for selecting a treatment regimen for a subject with leukemia

Info

Publication number
SG11201804020YA
SG11201804020YA SG11201804020YA SG11201804020YA SG11201804020YA SG 11201804020Y A SG11201804020Y A SG 11201804020YA SG 11201804020Y A SG11201804020Y A SG 11201804020YA SG 11201804020Y A SG11201804020Y A SG 11201804020YA SG 11201804020Y A SG11201804020Y A SG 11201804020YA
Authority
SG
Singapore
Prior art keywords
international
cpx
court
pct
subject
Prior art date
Application number
SG11201804020YA
Inventor
Max Gordon
Paul Tardi
Jeffrey Tyner
Lawrence Mayer
Original Assignee
Celator Pharmaceuticals Inc
Univ Oregon Health & Science
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celator Pharmaceuticals Inc, Univ Oregon Health & Science filed Critical Celator Pharmaceuticals Inc
Publication of SG11201804020YA publication Critical patent/SG11201804020YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Abstract

Continued on next page] () Title: ASSAYS AND METHODS FOR SELECTING A TREATMENT REGIMEN FOR A SUBJECT WITH LEUKEMIA (57) : Diagnostic methods for identifying cancer bearing subjects appropriate for treatment with CPX-351 include genetic and ex vivo testing of cells from a candidate subject. Combination treat- ment with CPX-351 and FLT-3 inhibitors improve CPX-351 uptake and toxicity. inib CPX and M dastautin C -0 C+M Figure 10C (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau 111111111M 11111111111111111111111111111111111111111111111111111111111111R111111111111111 (10) International Publication Number WO 2017/083592 Al WIPO I PCT (43) International Publication Date 18 May 2017 (18.05.2017) Lawrence; 2416 Carmaria Court, North Vancouver, BC V7J 3M4 (CA). (74) Agents: MURASHIGE, Kate, H. et al.; Morrison & Foer- ster LLP, 12531 High Bluff Drive, Suite 100, San Diego, CA 92130-2040 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, (51) International Patent Classification: A61K 31/00 (2006.01) A61P 35/02 (2006.01) A61P 35/00 (2006.01) C12Q 1/68 (2006.01) (21) International Application Number: PCT/US2016/061444 (22) International Filing Date: 10 November 2016 (10.11.2016) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/254,109 11 November 2015 (11.11.2015) US (71) Applicants: CELATOR PHARMACEUTICALS, INC. [US/US]; 200 PrincetonSouth Corporate Center, Suite 180, Ewing, NJ 08628 (US). OREGON HEALTH & SCI- ENCES UNIVERSITY [US/US]; 3181 S.W. Sam Jackson Park Road, Portland, OR 97201 (US). (72) Inventors: GORDON, Max; 3335 SW Corbett Ave, Port- land, OR 97239 (US). TARDI, Paul; 19081 Sundale Court, Surrey, BC V3S 7M6 (CA). TYNER, Jeffrey; 4310 SW Selling Court, Portland, OR 97221 (US). MAYER, W O 20 17 /0835 9 2 Al WO 2017/083592 Al MIDEDIMOM010101110101111EMOMINHOM0VOIMIE LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, Published: SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). with international search report (Art. 21(3))
SG11201804020YA 2015-11-11 2016-11-10 Assays and methods for selecting a treatment regimen for a subject with leukemia SG11201804020YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562254109P 2015-11-11 2015-11-11
PCT/US2016/061444 WO2017083592A1 (en) 2015-11-11 2016-11-10 Assays and methods for selecting a treatment regimen for a subject with leukemia

Publications (1)

Publication Number Publication Date
SG11201804020YA true SG11201804020YA (en) 2018-06-28

Family

ID=58695625

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202112699UA SG10202112699UA (en) 2015-11-11 2016-11-10 Assays and methods for selecting a treatment regimen for a subject with leukemia
SG11201804020YA SG11201804020YA (en) 2015-11-11 2016-11-10 Assays and methods for selecting a treatment regimen for a subject with leukemia

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10202112699UA SG10202112699UA (en) 2015-11-11 2016-11-10 Assays and methods for selecting a treatment regimen for a subject with leukemia

Country Status (15)

Country Link
US (3) US10927418B2 (en)
EP (1) EP3373919A4 (en)
JP (2) JP6976941B2 (en)
KR (1) KR20180108572A (en)
CN (2) CN108778260A (en)
AU (2) AU2016353163B2 (en)
BR (1) BR112018009463A8 (en)
CA (2) CA3005076C (en)
CO (1) CO2018005846A2 (en)
HK (1) HK1258724A1 (en)
IL (2) IL292080A (en)
MX (1) MX2018005771A (en)
MY (1) MY193531A (en)
SG (2) SG10202112699UA (en)
WO (1) WO2017083592A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY193531A (en) * 2015-11-11 2022-10-18 Celator Pharmaceuticals Inc Assays and methods for selecting a treatment regimen for a subject with leukemia
MX2021003527A (en) * 2018-09-25 2021-05-27 Celator Pharmaceuticals Inc Low-intensity treatment of hematological disorders.
WO2020102595A1 (en) * 2018-11-14 2020-05-22 Dana-Farber Cancer Institute, Inc. Determining treatment response in single cells
CN111870600B (en) * 2020-07-13 2022-04-15 中南大学湘雅二医院 New application of sorafenib, regorafenib and analogues or derivatives thereof
US11945785B2 (en) 2021-12-30 2024-04-02 Biomea Fusion, Inc. Pyrazine compounds as inhibitors of FLT3

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2388064T3 (en) 2004-04-22 2012-10-08 Celator Pharmaceuticals, Inc. Liposomal formulations of anthracycline agents and cytidine analogues
US20100303895A1 (en) 2007-02-16 2010-12-02 Arthur Louie Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders
WO2008111441A1 (en) 2007-03-05 2008-09-18 Kyowa Hakko Kirin Co., Ltd. Pharmaceutical composition
TWI546537B (en) * 2009-05-19 2016-08-21 維維亞生技公司 Methods for providing personalized medicine tests ex vivo for hematological neoplasms
US20120010229A1 (en) * 2010-07-08 2012-01-12 Macdougall John R Therapeutic regimens for hedgehog-associated cancers
CN104114156A (en) 2011-10-21 2014-10-22 切拉托尔制药公司 Lyophilized liposomes
WO2014087018A1 (en) * 2012-12-07 2014-06-12 Evotec (München) Gmbh Markers for responsiveness to an inhibitor of flt3
US9993551B2 (en) * 2014-09-13 2018-06-12 Novartis Ag Combination therapies of EGFR inhibitors
MY193531A (en) 2015-11-11 2022-10-18 Celator Pharmaceuticals Inc Assays and methods for selecting a treatment regimen for a subject with leukemia
MX2021003527A (en) * 2018-09-25 2021-05-27 Celator Pharmaceuticals Inc Low-intensity treatment of hematological disorders.

Also Published As

Publication number Publication date
US20210246512A1 (en) 2021-08-12
RU2018121249A (en) 2019-12-17
BR112018009463A2 (en) 2018-11-06
EP3373919A1 (en) 2018-09-19
EP3373919A4 (en) 2019-06-19
CA3219061A1 (en) 2017-05-18
US20180327854A1 (en) 2018-11-15
JP2018535975A (en) 2018-12-06
US10927418B2 (en) 2021-02-23
MX2018005771A (en) 2019-03-14
KR20180108572A (en) 2018-10-04
CN115414376A (en) 2022-12-02
IL259271B (en) 2022-05-01
US11746386B2 (en) 2023-09-05
AU2016353163A1 (en) 2018-06-07
CA3005076A1 (en) 2017-05-18
HK1258724A1 (en) 2019-11-15
AU2016353163B2 (en) 2022-09-29
SG10202112699UA (en) 2021-12-30
WO2017083592A1 (en) 2017-05-18
AU2022291559A1 (en) 2023-02-02
CA3005076C (en) 2024-01-02
US20230279503A1 (en) 2023-09-07
CN108778260A (en) 2018-11-09
IL292080A (en) 2022-06-01
CO2018005846A2 (en) 2018-08-21
RU2018121249A3 (en) 2020-03-17
JP6976941B2 (en) 2021-12-08
MY193531A (en) 2022-10-18
JP2022024031A (en) 2022-02-08
BR112018009463A8 (en) 2019-02-26
IL259271A (en) 2018-07-31

Similar Documents

Publication Publication Date Title
SG11201804020YA (en) Assays and methods for selecting a treatment regimen for a subject with leukemia
SG11201908719QA (en) Biomarkers and car t cell therapies with enhanced efficacy
SG11201910019PA (en) Microorganisms and methods for producing cannabinoids and cannabinoid derivatives
SG11201906891RA (en) Methods for the administration of certain vmat2 inhibitors
SG11201901126UA (en) Combination therapy for cancer
SG11201903155XA (en) Pharmaceutical compounds
SG11201804360XA (en) Mat2a inhibitors for treating mtap null cancer
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201907402SA (en) Population-based immunogenic peptide identification platform
SG11201900442PA (en) Sorting of t lymphocytes in a microfluidic device
SG11201810196RA (en) Cancer treatments
SG11201805828YA (en) Method of treating c3 glomerulopathy
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201909064RA (en) Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer
SG11201900554YA (en) Spiro-lactam nmda modulators and methods of using same
SG11201807593TA (en) Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
SG11201908602UA (en) Combination therapy for the treatment of solid and hematological cancers
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201909722WA (en) Methods and systems for high-throughput blood component collection
SG11201906852XA (en) Treatment of diuretic resistance
SG11201804440XA (en) Chemical reprogramming of human glial cells into neurons with small molecule cocktail
SG11201807255YA (en) Treatment of autoimmune diseases with combinations of rxr agonists and thyroid hormones
SG11201408808WA (en) Method and system for treatment of biological tissue
SG11201408171SA (en) Fbxo3 inhibitors